Octreotide Teva (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotide Teva, is a peptide synthetic analog of somatostatin presented as a 100 µg/mL solution for subcutaneous injection use. It regulates hormone secretion and is employed in the management of hormone‑secreting tumours and related complications in adults.

GNH USA supplies Octreotide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Octreotide Teva is a somatostatin analogue that modulates neuro‑endocrine activity in several disease families. - Acromegaly: reduces excessive growth hormone production and improves clinical symptoms. - Carcinoid syndrome: lessens flushing and diarrhoea associated with serotonin‑rich tumours. - VIPoma/Medullary thyroid carcinoma: controls severe diarrhoea and hormonal hypersecretion. - Preventive prophylaxis for postoperative pancreatic surgery complications including fistula and fluid collections. - Management of refractory hypoglycaemia in insulin‑oma patients who cannot undergo surgery 

Octrestone